Synaptic Failure In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Synaptic dysfunction and loss are among the earliest and most robust pathological features of neurodegenerative diseases. Synaptic failure precedes neuronal cell body degeneration and correlates strongly with cognitive decline in Alzheimer's disease, Parkinson's disease, and other disorders.
| Property |
Value |
| Category |
Neurodegenerative Disease Mechanism |
| Key Structures |
Synaptic vesicles, Active zones, Postsynaptic densities |
| Affected Neurotransmitters |
Glutamate, GABA, Acetylcholine, Dopamine, Serotonin |
| Associated Diseases |
Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia |
The presynaptic compartment includes:
- Synaptic vesicles containing neurotransmitters
- Active zone proteins (bassoon, piccolo, RIM, Munc13, synaptotagmin)
- Calcium channels (VGCC)
- Vesicle recycling machinery (clathrin, dynamin)
- Mitochondria for energy supply
The postsynaptic specialization contains:
- Neurotransmitter receptors (NMDA, AMPA, GABA, mGluR)
- Scaffold proteins (PSD-95, Homer, Shank)
- Signaling molecules
- Cytoskeletal proteins
- Protein synthesis machinery (for dendritic spines)
Toxic proteins directly impair synaptic function:
- Aβ oligomers bind to synapses, disrupting plasticity
- α-Synuclein impairs vesicle release
- Tau spreads trans-synaptically
- TDP-43 disrupts RNA processing at synapses
- Huntingtin impairs vesicular transport
Elevated intracellular calcium leads to:
- Excitotoxicity through NMDA receptors
- Mitochondrial calcium overload
- Protease activation (calpains)
- Synaptic vesicle depletion
- Impaired vesicle recycling
Energy failure at synapses causes:
- Reduced ATP for vesicle cycling
- Impaired calcium buffering
- Increased oxidative stress
- Loss of synaptic mitochondria
- Vesicle release failure
Impaired transport disrupts:
- Vesicle delivery to terminals
- Organelle maintenance
- Synaptic protein synthesis
- Neurotrophin signaling
- Mitochondrial distribution
flowchart TD
A[Toxic Proteins] --> B[Synaptic Dysfunction)
A --> C[Calcium Dysregulation] -->
A --> D[Axonal Transport Defects)
B --> E[ vesicle Release Failure] -->
B --> F[Receptor Internalization] -->
C --> G[Mitochondrial Stress] -->
D --> H[Energy Failure] -->
E --> I[Neurotransmitter Failure] -->
F --> J[Synaptic Plasticity Loss] -->
G --> K[Oxidative Stress)
H --> I
K --> L[Synaptic Loss)
I --> L
J --> L
L --> M[Cognitive Decline]
- NMDA Receptor Signaling: Excitotoxicity, LTD induction
- AMPA Receptor Trafficking: Synaptic strength modulation
- BDNF/TrkB Signaling: Synaptic plasticity, survival
- cAMP/PKA Pathway: Synaptic plasticity, LTP
- mTORC1 Pathway: Protein synthesis, synaptic growth
- Aβ oligomers bind to prion protein
- Synaptic NMDA receptor dysfunction
- Mushroom spine loss
- Impaired LTP
- Early marker: Synaptic loss
- Dopaminergic terminal loss
- α-Synuclein at synapses
- Impaired vesicle release
- Mitochondrial complex I deficiency
- Synuclein spreading
- Neuromuscular junction denervation
- Synaptic vesicle accumulation
- Presynaptic protein aggregation
- Calcium dysregulation
- Excitotoxicity
| Target |
Approach |
Status |
| Aβ-synapse binding |
Anti-oligomer antibodies |
Clinical trials |
| Calcium homeostasis |
NMDA modulators |
Clinical trials |
| Synaptic plasticity |
BDNF mimetics |
Research |
| Axonal transport |
Microtubule stabilizers |
Research |
| Neurotransmission |
Symptomatic drugs |
Approved |
The study of Synaptic Failure In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298(5594):789-791.
- Wishart TM, Parson SH, Gillingwater TH. Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol. 2006;65(8):733-739.
- Harris JF, Micheva KD, Martin SE. Assessing synapse formation and function. Nat Methods. 2019;16(1):3-5.
- Sheng M, Kim E. The postsynaptic density. Annu Rev Neurosci. 2000;23:1-27.
- Calabrese B, Halpain S. Actin and the dynamic architecture of dendritic spines. Neuroscientist. 2006;12(5):392-398.
- Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density. Cereb Cortex. 2007;17(3):525-537.
- Bellucci A, Mercuri NB. alpha-Synuclein and synaptic dysfunction: a dangerous liaison. Mov Disord. 2020;35(10):1778-1792.
- Dodd CA, Klein BG. Synaptic dysfunction and intracellular signaling in Parkinson's disease. J Neurosci Res. 2022;100(1):33-46.
- VanSaun M, Srivastava A, Nimmanapalli R. Amyotrophic lateral sclerosis: synaptic mechanisms. Front Neurosci. 2021;15:750894.
- Henstridge CM, Sideris DI, Carroll E, et al. Synapse loss in the prefrontal cortex in aging and Alzheimer's disease. Nat Aging. 2022;2(1):50-61.
- McQuail JA, Frazier CJ, Bizon JL. Molecular aspects of age-related cognitive decline. Neurobiol Aging. 2015;36(12):3163-3182.
- Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204-1222.
- Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau in Alzheimer's disease. Neuron. 2014;81(1):46-59.
- Reddy PH, Mani G, Park BS, et al. Differential loss of synaptic proteins in Alzheimer's disease. J Neurochem. 2018;145(3):251-262.
- Petzold GC, Singleton MD, De Zeeuw P. Synaptic dysfunction in Alzheimer's disease. Handb Clin Neurol. 2022;184:417-438.
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 45%